Replies to post #519557 on NorthWest Biotherapeutics Inc (NWBO)

[LearningEveryTrade]

Optune is a device, not a biologic, so, much easier to gain approval.

NVCR completed their Phase 3 trial with no disruptions and gained approvals by numerous regulators. Let's see what happens with NWBO's dubious trial and an application if they can actually complete one.

Average time for new drug is 15 years. That is without Covid delay or new discovery of psuedoprogression. That got worked out over 2 years and here were are, right on time !!!

Dr. Anna Barker saying pharma takes 15 years and $2 Billion dollars to get to market. That's for Big Pharma, let alone the 'lil $NWBO. We are Right On Time and budget !! Video Sept. 2022. #DCVAX #NWBO pic.twitter.com/RsKB99fAw9

— LearningEveryTrade 🚀📈💰 (@EveryTrade) September 28, 2022

Endpoints changed well before data lock. AF acknowledges that .

NWBO took 16 YEARS to complete a clinical trial. Had a partial stop in the trial. Manipulated the protocol, comparator, endpoints and SAP after the close of the trial.
There is NOBODY that has managed a trial so poorly.

[Dr Bala]

The helmet will be obsolete when the DCVax-L therapy becomes the new SOC.

[SkyLimit2022]

I know exactly what you mean—You’re saying that everyone should do their own independent research about the DCVax global P3 and research the clinical investigators who designed and led the trial to verify that the trial that was conducted at 94 sites worldwide was in fact led by two clinical trial experts and that long term survivors who were trial participants are still alive today.

So many of these survivor stories are old news— research 2022 updates—some are GBM patients surpassing a decade or multiple decades—miraculous …

https://www.hawaii.edu/news/2017/03/30/newirth-laker-for-a-day/

Clinical Trial Experts:

Dr. Linda Liau is a world-renowned neuro-oncologist, surgeon, and educator at UCLA where she is also the chair of the department of neurosurgery. As her paper on DCVax moves through the independent peer review process, it is interesting to note that she was once the editor-in-chief of a neuro-oncology medical journal: Dr. Liau has authored over 170 peer-reviewed research articles, along with several book chapters, and a textbook entitled Brain Tumor Immunotherapy. She is on the editorial boards of several scientific/medical journals and was the Editor-in-Chief of the Journal of Neuro-Oncology (2007–2017).

https://www.uclahealth.org/providers/linda-liau

Across the pond from Dr. Liau, Dr. Ashkan was the chief investigator of the DCVax trial for patients in Europe. At King’s College in London, Ashkan is the lead clinician for neuro-oncology and the chair of the King’s Neurosciences Clinical Trial Unit. He is a world-renowned cancer trial expert. A few years ago, Professor Ashkan was named the UK Clinician of the Year by The Brain Tumour Charity. Additionally, Ashkan serves as an advisor to the U.K. government.

https://www.kcl.ac.uk/people/keyoumars-ashkan
—————————————
https://soc-neuro-onc.org/
Autologous tumor lysate-loaded dendritic cell vaccination improves survival in patients with newly diagnosed and recurrent glioblastoma: survival results from a phase 3 trial Plenary Abstract Presenter: Linda M. M. Liau, MD PhD
- University of California, Los Angeles

https://virtualtrials.org/dcvax.cfm

[SkyLimit2022]

NVCR share holders aren’t buying your narrative. NVCR has a very dubious business outlook and future. Look at all the serious risks that they have buried in their SEC filing… it is no wonder that the share holders are heading for the exits. Novocure is down to a third of its share price since the peak just one year ago in June when it was over $200.

Look at all risks buried in their SEC filing on pages 25-51 of the document linked below. They have 26 pages of product efficacy risks, regulatory risks, legal risks, financial risks, market competition risks… etc etc. They admit under penalty of perjury that their company has serious risks.

You posted a million times about NWBO’s “SEC filings” but never say a word about the 25 pages of serious risks filed for same fiscal year for NVCR. Why not?

NVCR SEC Filing:
https://d18rn0p25nwr6d.cloudfront.net/CIK-0001645113/c5eca622-306f-417f-931b-c2ab018fa6b6.pdf#page25

[skitahoe]

I believe that you couldn't be more wrong about the number of companies who failed because they simply couldn't afford to take their product through what was necessary for approval. I'm speaking of companies that tried their product on the fast killing cancers, like pancreatic in spite of preclinical and early clinical data that indicated it was far more effective against something like colon cancer. They gambled on pancreatic because the trial would be smaller and shorter and that was all they could afford, when it failed they were out of business.

Sure, sometimes BP will purchase these product for potential future development, but sometimes they're just abandoned as the company goes out of business, or somehow struggles to stay in business, but can't afford the needed trials.

NWBO took on one of the toughest cancers known to man, yes they had delays, but they have succeeded, whether you believe it or not.

Gary